Plain-English translation of NCT06147960 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are studying a specific protein pattern in cervical cancer tumors to better predict which patients are at higher risk for cancer recurrence within two years after treatment. This study examines existing tumor samples and medical records from women who have already completed radiation and chemotherapy for advanced cervical cancer. The goal is to identify patients who might benefit from different or additional treatment approaches.
Currently, doctors cannot always predict which women with advanced cervical cancer will have their cancer return after standard treatment. If researchers can identify a protein pattern that predicts recurrence, doctors could offer different treatment options earlier to patients at highest risk, potentially improving survival rates.
You likely qualify if…
You likely don't qualify if…
This is a research study of existing medical records and tumor samples, not a treatment trial. Researchers will review your medical records and examine the biopsy tissue that was already taken before your radiation and chemotherapy treatment. There are no study visits, medications to take, or additional procedures required from you as a participant.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
France
Collaborators
Institut du Cancer de Montpellier - Val d'Aurelle
Enrollment target
~180 participants
Started
September 2024
Primary completion
May 2027
Age range
18 Years and older
Sex
Female only
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Frédéric FITENI, Dr.
Nîmes University Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.